CDC Advisory Committee Delays Vote on Proposed Changes to Newborn Hepatitis B Vaccination Schedule
核心洞察
The CDC's Advisory Committee on Immunization Practices (搜索) postponed a vote that would have delayed the first hepatitis B vaccine dose from within 24 hours of birth to one month of age for infants whose mothers test negative for the virus.
Universal newborn vaccination has achieved a 95% reduction in childhood hepatitis B (搜索) infections since 1991, dropping from 18,000 annual cases to fewer than 1,000 today.
The proposed change would leave infants unprotected during the most vulnerable period when infection is most likely to become chronic and cause lifelong liver (搜索) damage.
The Centers for Disease Control and Prevention (搜索)'s Advisory Committee on Immunization Practices (搜索) has postponed a critical vote on proposed changes to the hepatitis B (搜索) vaccination schedule for newborns. The committee, which met on September 18-19, 2025, was set to consider delaying the first dose from within 24 hours of birth to one month of age for infants whose mothers test negative for hepatitis B virus.
The proposed change would maintain the current recommendation for immediate vaccination only for infants born to mothers with confirmed hepatitis B (搜索) infections, while allowing parents of other newborns to choose earlier vaccination if desired. However, the committee tabled the vote on September 19, delaying the decision to the next meeting scheduled for October 22-23.
Dramatic Success of Current Vaccination Strategy
The universal newborn hepatitis B (搜索) vaccination program, implemented in 1991, represents one of the most successful public health interventions in recent decades. Before widespread vaccination, approximately 18,000 children contracted hepatitis B annually before their 10th birthday, with about half of these infections occurring at birth.
The impact has been profound. Today, fewer than 1,000 U.S. children or adolescents contract the virus each year—a 95% reduction from pre-vaccination levels. Perhaps most significantly, fewer than 20 babies are now reported infected at birth, compared to the thousands who were infected annually in the pre-vaccine era.
U.S. hepatitis B (搜索) infection rates have dropped nearly 90%, from about 9.6 per 100,000 before vaccination became widespread to approximately one per 100,000 in 2018, according to CDC data.
Critical Window of Vulnerability
The timing of hepatitis B (搜索) vaccination is crucial due to the virus's devastating impact on infants. Hepatitis B becomes chronic in more than 90% of infected infants, compared to most adults who can clear the infection naturally. Without preventive treatment or vaccination, 70% to 90% of infants born to infected mothers will become infected, with 90% of those infections becoming chronic.
The consequences are severe: one in four children chronically infected with hepatitis B (搜索) will die prematurely from cirrhosis (搜索) or liver cancer (搜索). The infection silently damages the liver (搜索) over decades, potentially leading to liver failure (搜索) requiring transplantation. Because there is no cure for hepatitis B infections, patients often experience recurrent liver disease even after transplant.
Universal Approach Addresses Critical Gaps
The current universal vaccination strategy addresses several critical gaps that a risk-based approach cannot cover. Universal birth dosing protects infants whose parents' hepatitis B (搜索) status is unknown or was not tested during prenatal care. Maternal testing can also miss recent infections, making universal newborn vaccination more reliable.
Before 1991, public health guidance recommended hepatitis B (搜索) vaccination only for high-risk newborns, such as those born to infected mothers. This targeted approach failed, with tens of thousands of children still becoming infected annually. Some newborns were exposed when their mothers weren't properly screened or became infected late in pregnancy.
Children also became infected through household contacts or childcare settings through exposures as ordinary as shared toothbrushes or bites that break the skin. Because hepatitis B (搜索) can survive for a week on household surfaces, and many carriers are unaware they are infected, even babies and toddlers of uninfected mothers remained at risk.
Current Vaccination Guidelines
Since October 2016, the CDC's Advisory Committee on Immunization Practices (搜索) has recommended that all medically stable newborns receive the first dose of hepatitis B vaccine within 24 hours of birth, followed by doses at 1-2 months and 6-18 months of age. This replaced the previous 2005 recommendation calling for the initial dose before hospital discharge.
For infants born to mothers with active hepatitis B (搜索) infections, the birth dose is administered within 12 hours along with special antibodies to fight the virus. Currently, 0.7% to 1.1% of infants born to infected mothers develop infection after vaccination at birth.
About 80% of parents currently choose to follow CDC guidance and vaccinate their babies at birth. The hepatitis B (搜索) vaccines used in the U.S. have an outstanding safety record, with the only confirmed risk being anaphylaxis occurring in roughly 1 in 600,000 doses. No child has died from such a reaction, and extensive studies show no link to other serious conditions.
Global Impact and Adoption
The success of universal newborn hepatitis B (搜索) vaccination extends globally. As of 2020, 190 of the 194 World Health Organization member countries had adopted the practice, with more than half providing vaccination to all newborns immediately after birth. The World Health Organization estimates that 254 million people worldwide were living with chronic hepatitis B infection in 2022, with 1.2 million new infections each year.
Unprecedented Committee Changes
The proposed vote occurs amid significant changes to the advisory committee structure. In June 2025, Secretary of Health and Human Services Robert F. Kennedy Jr. disbanded the entire committee and handpicked new members. According to experts, the committee's long-standing procedures to evaluate evidence supporting vaccine risks and benefits are not being followed in this case, despite the proposed change not being based on any new evidence.